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A
s part of a National Uni-
versity of Singapore (NUS) 
research project, Dr Martin 
Lear from NUS Depart-
ment of Chemistry and Dr Kevin Tan 
from the NUS Department of Micro-
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that has been used in the treatment 
of malaria since 1947. 
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molecule, known as LynxTag–CQ, 
demonstrated the same biological ac-
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are now able to visualize intracellular 
drug-cell interactions, in an easy and 
cost-effective manner.
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Lynx Tag, the two gave a thought to 
commercialize the technology and 
hence formed BioLynx, a biotech 
company. The company was formed 
to provide research tools targeting 
international malaria research, and 
to focus on developing and com-
mercializing its LynxTag technol-
ogy platform for other drugs and 
diseases.
The company believes that malaria 
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useful research tool for studying top-
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drug uptake, mechanism of drug ac-
tion, or chemo-sensitization.
“We already validated LynxTag-CQ 
as a research tool for malaria re-
search. In addition, we believe it has 
greater potential and can be used to 
study mechanisms of other diseases 
at a cellular level. For example, chlo-
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diseases, cancer and some viral in-
fections. Moving forward, we plan 
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pipeline of products and synthesize 
chemical tags for other high value 
drugs,” says Dr Kevin Tan, co-found-
er of BioLynx. 
LynxTag-CQ is currently the only 
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in the market and is available in a 
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troduce LynxTag-CQ for the research 
community, BioLynx is providing 
some 100 free samples internation-
ally in which each sample contains 
50 tests. 
BioLynx plans to commence sales 
of LynxTag-CQ from the beginning 
of 2012, pricing it at S$500 per box 
(with 100 tests per box). LynxTag 
products aim to provide a solution 
for direct visualization of drug action 
and localization on samples, such as 
blood and tissue samples. Qualitative 
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croscopy in a research laboratory can 
then be obtained for studies involv-
ing relevant topics such as malaria.
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drugs have been validated to be phar-
macologically similar to their parent 
drugs, thus allowing both visualiza-
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ity. Its high versatility also allows it to 
be applied to a wide range of drugs, 
enabling studies on drug resistance, 
localization and sensitivity.
BioLynx has raised $0.7 million 
(S$1 million) in funding, includ-
ing research grants from Singapore 
government agencies and personal 
investments from the founders. The 
funding is being used to commercial-
ize the technology and bring it to the 
market. The company is looking for 
more investments to grow and mar-
ket its product internationally.
???????????????????????????????????
????? ?? ???? ??????? ???????????? ????
???? ???????????????????? ????????????
molecule, and has licensed the tech-
nology exclusively to BioLynx.
We validated LynxTag-CQ as 
a research tool for malaria 
research and believe it has 
greater potential and can be 
used to study mechanisms of 
other diseases at a cellular 
level
Dr Kevin Tan 
co-founder, BioLynx.
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BioLynx was formed to 
provide research tools 
targeting international 
malaria research, and 
to focus on developing 
and commercializing 
its LynxTag technology 
platform for other drugs 
and diseases
